Edwards Lifesciences Corporation (EW) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Edwards Lifesciences Corporation (EW:NYSE), powered by AI.

Current Price
$85.11
P/E Ratio
46.4
Market Cap
49.8B
Sector
Healthcare
What is the Edwards Lifesciences Corporation stock price forecast?

Edwards Lifesciences Corporation is currently trading at $85.11. View real-time AI analysis on Alpha Lenz.

What is Edwards Lifesciences Corporation insider trading activity?

View the latest insider trading data for Edwards Lifesciences Corporation on Alpha Lenz.

What is Edwards Lifesciences Corporation's P/E ratio?

Edwards Lifesciences Corporation's P/E ratio is 46.4.

Edwards Lifesciences Corporation

NYSE · EW
$85.11-0.65(-0.76%)Pre-marketNYSE regular session 09:30–16:00 ET
Ask about Edwards Lifesciences Corporation's future dividend policy...
Alpha Chat Insight

Edwards Lifesciences Corporation trades at a P/E of 46.4 (premium valuation) with solid ROE of 10.6%. Operating margin of 27.0% indicates strong profitability.

Ask for details

Company Overview

Edwards Lifesciences Corporation is a leading healthcare company primarily known for its innovative medical devices focused on cardiovascular conditions. The firm's primary function revolves around the development and commercialization of heart valve products and hemodynamic monitoring systems, aimed at enhancing the life quality of patients suffering from cardiovascular diseases. Edwards Lifesciences plays a crucial role in the healthcare sector, particularly impacting the cardiology and surgical fields. Notable for its pioneering work in heart valve therapies, the corporation is at the forefront of transcatheter aortic valve replacement (TAVR) technology, a minimally invasive procedure that offers a significant alternative to traditional open-heart surgeries. Edwards Lifesciences collaborates closely with healthcare professionals to ensure its products address critical medical needs globally. Headquartered in Irvine, California, Edwards Lifesciences operates in a highly competitive and rapidly advancing market, where technological innovation and patient outcomes are pivotal. Its contributions continue to set standards within the medical device industry, reinforcing its market significance by addressing demands for effective cardiovascular care solutions worldwide.

CEOMr. Bernard J. Zovighian
SectorHealthcare
IndustryMedical Devices
Employees15,800

Company Statistics

FY 2025

Profile

$49.77BMarket Cap
$6.07BRevenue
0.00Shares Out
15,800Employees

Margins

78.01%Gross
32.38%EBITDA
26.97%Operating
20.98%Pre-Tax
17.62%Net

Valuation

46.36P/E
4.81P/B
8.20EV/Sales
24.20EV/EBITDA
37.28P/FCF

Growth (CAGR)

4.08%Rev 3Yr
6.70%Rev 5Yr
-2.94%Op Inc 3Yr
4.44%Op Inc 5Yr
-11.10%Net Inc 3Yr
5.37%Net Inc 5Yr

Returns

7.99%ROA
10.56%ROE
9.67%ROIC

Financial Health

$2.94BCash & Cash Equivalents
$421.60MNet Debt
32.50%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Edwards Lifesciences Corporation (ticker: EW) is a company listed on NYSE in the Healthcare sector (Medical Devices). It has approximately 15,800 employees. Market cap is $49.8B.

The current price is $85.11 with a P/E ratio of 46.36x and P/B of 4.81x.

ROE is 10.56% and operating margin is 26.97%. Annual revenue is $6.1B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Edwards Lifesciences Corporation (EW) Stock Forecast 2026 $85.11 — Price, Financials & Analyst Targets | Alpha Lenz